VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the World Muscle Society 2021 Virtual Conference
PARAMUS, N.J., Sept. 17, 2021 /PRNewswire/ --NS Pharma, Inc.. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension (up to 192 weeks) of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the World Muscle Society 2021 Virtual Conference being held September 20–24.
The electronic poster presentation will be given by Paula Clemens, MD from the University of Pittsburgh School of Medicine on Thursday, September 23rd from 16:30 to 18:30 BST. For more information, please visit the World Muscle Society Virtual Conference website to view the full program: https://www.wms2021.com/page/programme.
About VILTEPSO® (viltolarsen) injection
Important Safety Information
Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
About NS Pharma, Inc.
View original content:https://www.prnewswire.com/news-releases/viltepso-viltolarsen-injection-interim-long-term-clinical-trial-data-scheduled-for-presentation-at-the-world-muscle-society-2021-virtual-conference-301379083.html
SOURCE NS Pharma